【EXPERT Q&A】What are the core requirements that manufacturers need to master for the usability testing of in vitro diagnostic medical devices under the EU IVDR?

November 13, 2026  Source: drugdu 31

Drugdu.com expert's respons

 

When in vitro diagnostic medical device enterprises prepare to apply for EU IVDR CE certificates, apart from analytical performance, clinical performance and the quality management system, they also need to pay close attention to product Usability.

Some enterprises believe that as long as indicators such as the sensitivity, specificity and accuracy of reagents meet the requirements, the product performance has been fully demonstrated. However, in actual use, even if the detection principle and performance are flawless, if users cannot operate the equipment, collect samples or interpret results correctly, it may still lead to test failures, and even affect subsequent clinical judgments.

This is especially true for home self-test reagents, point-of-care testing (POCT) devices, and IVD devices with software operation interfaces, where users vary greatly in professional expertise, operating environments and usage habits. For these products, usability evaluation is a key priority that manufacturers must take into account.

What requirements does IVDR set for usability?

The EU Regulation on in vitro diagnostic medical devices (EU 2017/746) does not mandate a completely identical usability testing scheme for all IVD products, but it explicitly requires manufacturers to identify and control potential risks that may arise during product use.

Clause 5 of Appendix I of IVDR stipulates that when reducing the risk of use errors, manufacturers shall take into account the ergonomic characteristics of the device, the intended use environment, as well as factors such as users' technical knowledge, experience, education level, training status and physical conditions.

For self-testing and near-patient testing products, Clause 19 of Appendix I puts forward additional specific requirements. Manufacturers need to consider the operational capabilities of intended users, as well as the impact of differences in usage methods and environments on product performance, to ensure that users can complete tests safely and accurately, and minimize the risk of errors in sample processing, device operation and result interpretation as much as possible.

For example, a home rapid test reagent can deliver accurate results when operated by laboratory personnel, but ordinary users may get compromised test results due to insufficient sampling, incorrect sample loading volume, inaccurate waiting time, or misinterpretation of weakly positive results.

These problems cannot be solved solely by conventional analytical performance tests, and corresponding evaluations need to be carried out in combination with real usage scenarios.

What should usability testing focus on?

Enterprises first need to clarify the intended users and use environment of their products.

Users of different types of IVD products vary greatly. Professional laboratory testing equipment is usually operated by trained personnel, point-of-care testing devices may be used by nurses or other medical staff, and self-test reagents are directly targeted at ordinary consumers with no medical background.

Therefore, the test subjects and usage scenarios must be consistent with the intended use declared for the product. It is not acceptable to let only R&D personnel who are very familiar with the product complete the operations, and then directly use the test results as proof that ordinary users can use the product safely.

In actual evaluations, key links including sample collection, reagent preparation, device operation, testing process, result reading and abnormal situation handling need to be prioritized.

For example, whether users can correctly identify the sample collection volume, complete the sample loading as required, distinguish between valid and invalid test results, and know how to deal with device alarms or operational errors when they occur.

For IVD instruments with software interfaces, this may also involve menu operations, information input, result display, alarm prompts and data management. Unclear interface design, overly complicated operation steps or inconspicuous warning information will all increase the risk of use errors.

During testing, reasonably foreseeable misuse patterns should also be considered, to analyze whether these errors may affect test results or user safety, and corresponding risk control measures shall be taken based on the assessment.

According to what standards should usability evaluation be carried out?

IEC 62366-1 Medical devices - Part 1: Application of usability engineering to medical devices is a key reference standard for enterprises to carry out usability engineering.

This standard emphasizes identifying safety-related user interface features, potential use errors and hazardous use scenarios through a systematic usability engineering process, and reducing use risks through design, evaluation and verification.

In practice, enterprises usually establish usability engineering documents in accordance with IEC 62366-1, including analysis of intended users and use environments, key operational tasks, use risk analysis, user interface design and evaluation records.

Usability evaluation generally includes formative evaluation and summative evaluation. Formative evaluation is mainly used to identify problems and improve designs during the product development process; summative evaluation is used to confirm whether the final or representative user interface can support intended users to use the product safely.

It should be noted that IEC 62366-1 provides a usability engineering methodology. Enterprises still need to determine the evaluation scope in combination with the applicable IVDR clauses, product risks and usage characteristics. They cannot simply complete a usability test report and assume that all regulatory requirements have been met.

Why do self-test reagents require more emphasis on user testing?

For self-test IVD products targeted at ordinary consumers, manufacturers need to provide evidence that the product is suitable for use by non-professional personnel.

Section 5.1 of Appendix IX of IVDR sets forth additional requirements for the technical document review of Class B, C and D self-test and near-patient testing products, including research results carried out on intended users, data demonstrating that the product is suitable for corresponding use scenarios, as well as documents such as labels and instructions for use.

For example, before a home urine test reagent enters the EU market, the manufacturer needs to evaluate whether ordinary users can independently complete the test operation, correctly interpret positive, negative and invalid results, and whether the instructions are sufficient to help users avoid common operational errors.

If testing finds that users frequently misjudge invalid results as negative, the enterprise needs to analyze the root cause, which may involve the way results are displayed, the wording of the instructions or the product design, and take improvement measures based on the associated risks.

This type of testing should not only focus on whether users find the product easy to use, but also assess whether use errors may cause safety risks, and whether relevant risk control measures are effective.

For some near-patient testing devices that require training to use, it is also necessary to clearly define the knowledge and training conditions that intended users are required to have, and evaluate the usability of the product under these corresponding conditions.

What evidence needs to be provided in the usability test report?

When preparing IVDR technical documents, enterprises need to ensure that the usability evaluation is mutually consistent with the risk management and product performance documentation.

It is usually necessary to record the evaluation purpose, product version, intended users, use environment, test tasks, basis for sample selection, test methods, acceptance criteria, observation results, use errors and their analysis, risk control measures and final conclusions.

For example, if an enterprise finds in the testing process that some users cannot correctly read test results, it cannot just record "user operation failure" in the report. Instead, it needs to analyze the cause of the failure, determine whether there is a safety risk, and specify what design improvements or other control measures have been taken.

If the problem is resolved by modifying the instructions, optimizing the operation interface or adjusting the product structure, necessary re-evaluation shall be carried out according to the impact of the change to prove that the risks have been properly controlled.

At the same time, the product model, software version, labels and instructions involved in the usability study shall be consistent with the actual declared product. Whether tests completed with early development versions can support the final marketed version requires a reasonable difference assessment.

Regarding the number of samples, IVDR does not stipulate that all IVD products must adopt a fixed unified number of test participants. Enterprises shall determine a reasonable test scale based on the intended user group, use risks, product complexity and evaluation purpose, and explain the selection rationale.

Is it necessary to continue usability work after the product obtains the CE marking?

Usability evaluation should not stop after the product obtains the CE marking.

In accordance with the post-market surveillance requirements of IVDR, manufacturers need to continuously collect and analyze relevant information during product use, including complaints, use errors, test failures and other issues that may affect safety and performance.

For home self-test reagents, repeated occurrences of sampling errors, result misinterpretation or inability to understand the instructions among users may indicate that the existing design or risk control measures still need to be improved.

For professional IVD equipment, updates to the operation interface, changes to software functions, and adjustments to the testing process may also affect the conclusions of the original usability evaluation.

Manufacturers shall assess whether it is necessary to update risk management documents, instructions for use, user training materials or supplement usability tests based on post-market data and product changes.

For IVD manufacturers planning to expand into the EU market, it is recommended to clarify the intended users, key operation steps and potential use risks at the product design and development stage, and plan the usability evaluation in parallel. Starting to supplement relevant tests only when submitting IVDR technical documents may lead to the discovery that adjustments to the instructions, user interface or product design are still needed.

On professional pharmaceutical and medical device B2B platforms such as Drugdu.com, when enterprises showcase their IVD products, they should also accurately specify whether the products are intended for professional laboratories, near-patient testing or home self-testing, and provide operation instructions, key performance information and relevant compliance documents that match the intended use.

For overseas purchasers, both the testing performance and use conditions of a product are important. Especially for self-test products, buyers also need to understand whether ordinary users can complete the test safely and correctly, and whether the manufacturer can provide necessary technical and documentation support.

The core of usability evaluation under EU IVDR is to confirm that the product can be operated safely and correctly by target users in the intended use environment, and that use errors that may affect test results are reasonably controlled.

Manufacturers should integrate usability engineering with risk management, performance evaluation, labeling and instructions for use, and post-market surveillance, and form corresponding evidence based on product risks and usage characteristics. For self-test and near-patient testing products, they shall also strictly implement the user suitability and technical document review requirements specified in IVDR, and avoid proving that the product meets actual use demands solely based on laboratory performance test results.

"/

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.